Micro<scp>RNA</scp>‐206 induces <scp>G</scp>1 arrest in melanoma by inhibition of <scp>CDK</scp>4 and <scp>C</scp>yclin <scp>D</scp>
Robert W. Georgantas, Koustubh Ranade, Laura K. Richman(University of Pennsylvania), Philip Z. Brohawn(Hofstra University), Lydia Greenlees, Bahija Jallal(Unknown), Brandon W. Higgs(Parker Institute for Cancer Immunotherapy), Katie Streicher(AstraZeneca (United States)), Zheng Liu(Hunan University of Traditional Chinese Medicine), Wei Zhu(Ministry of Education of the People's Republic of China), Xiaobing Luo(Panyu Hospital of Chinese Medicine), Yihong Yao(University of Science and Technology Beijing), Christopher Morehouse
Cited by 66
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Type I Interferon: Potential Therapeutic Target for Psoriasis?
|PLoS ONE|2008|308